Resources

Presented in February 2019 by: Sharmila Dorbala, MD, MPH, FASNC; Ronald M. Witteles, MD; Mazen Hanna, MD; and Martha Grogan, MD,

Presented in March 2019 by: Sharmila Dorbala, MD, MPH, FASNC; Jamieson Bourque, MD; Frederick Ruberg, MD; and Wael Jaber, MD.

Presented in May 2019 by: Sharmila Dorbala, MD, MPH, FASNC; Prem Soman, MD, MASNC; Rodney Falk, MD; and Mathew Maurer, MD.

ARC's comprehensive research strategy promotes a "from the patient's bedside back to bench" model, where patient's needs drive our prioritized portfolio of research. Read in detail our research strategy, and learn how we intend to achieve and measure our goals.

ARC’s research on Hereditary Transthyretin Amyloidosis (hATTR): Burden of Disease and Treatment Perspectives, was presented at the XII Paulista Congress of Neurology in Brazil. The English version of the poster is translated from Portuguese, and the data can be used by the Brazilian HTA during their evaluation of new treatments for patients with hATTR neuropathy.

Amyloidosis Research Consortium Cardiac Amyloidosis Survey: Results from Patients with AL and ATTR Amyloidosis and their Caregivers, was presented at the XVIth International Symposium on Amyloidosis from March 26-29, 2018 in Kumamoto, Japan. This poster presents results from 699 patients and caregivers and highlights the complex and burdensome diagnostic journey in amyloidosis.

The white paper contains the highest priorities and a research framework for the systemic amyloidosis diseases. This consensus document was developed through a rigorous process with the participation of 71 international experts from academic, clinical, regulatory, patient advocacy, health policy, industry, and other key areas. This publication is intended to identify, improve and accelerate a drug development pathway for the systemic amyloidosis diseases.

Medscape is the leading online global destination for physicians and healthcare professionals worldwide with the latest medical news and expert perspectives; drug and disease information; and professional education and CME classes specific for amyloidosis.